These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22178100)

  • 1. CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes.
    Singh R; Singh S; Briles DE; Taub DD; Hollingshead SK; Lillard JW
    Vaccine; 2012 Feb; 30(6):1181-90. PubMed ID: 22178100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A.
    Singh R; Singh S; Sharma PK; Singh UP; Briles DE; Hollingshead SK; Lillard JW
    PLoS One; 2010 Feb; 5(2):e9432. PubMed ID: 20195541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCL5 modulates pneumococcal immunity and carriage.
    Palaniappan R; Singh S; Singh UP; Singh R; Ades EW; Briles DE; Hollingshead SK; Royal W; Sampson JS; Stiles JK; Taub DD; Lillard JW
    J Immunol; 2006 Feb; 176(4):2346-56. PubMed ID: 16455992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A.
    Singh R; Gupta P; Sharma PK; Ades EW; Hollingshead SK; Singh S; Lillard JW
    Immunology; 2014 Apr; 141(4):514-30. PubMed ID: 24138116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen.
    Park SM; Ko HJ; Shim DH; Yang JY; Park YH; Curtiss R; Kweon MN
    J Immunol; 2008 Nov; 181(9):6447-55. PubMed ID: 18941235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PsaA (pneumococcal surface adhesin A) and PspA (pneumococcal surface protein A) DNA vaccines induce humoral and cellular immune responses against Streptococcus pneumoniae.
    Miyaji EN; Dias WO; Gamberini M; Gebara VC; Schenkman RP; Wild J; Riedl P; Reimann J; Schirmbeck R; Leite LC
    Vaccine; 2001 Dec; 20(5-6):805-12. PubMed ID: 11738744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae.
    Bosarge JR; Watt JM; McDaniel DO; Swiatlo E; McDaniel LS
    Infect Immun; 2001 Sep; 69(9):5456-63. PubMed ID: 11500417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
    Yamamoto M; McDaniel LS; Kawabata K; Briles DE; Jackson RJ; McGhee JR; Kiyono H
    Infect Immun; 1997 Feb; 65(2):640-4. PubMed ID: 9009325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cord blood Streptococcus pneumoniae-specific cellular immune responses predict early pneumococcal carriage in high-risk infants in Papua New Guinea.
    Francis JP; Richmond PC; Strickland D; Prescott SL; Pomat WS; Michael A; Nadal-Sims MA; Edwards-Devitt CJ; Holt PG; Lehmann D; van den Biggelaar AH
    Clin Exp Immunol; 2017 Mar; 187(3):408-417. PubMed ID: 27859014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection.
    Kye YC; Park SM; Shim BS; Firdous J; Kim G; Kim HW; Ju YJ; Kim CG; Cho CS; Kim DW; Cho JH; Song MK; Han SH; Yun CH
    Acta Biomater; 2019 May; 90():362-372. PubMed ID: 30922953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of IgG anti-capsular polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in the presence of cognate CD4+ T cell help.
    Khan AQ; Lees A; Snapper CM
    J Immunol; 2004 Jan; 172(1):532-9. PubMed ID: 14688364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy.
    Dorosti H; Eslami M; Nezafat N; Fadaei F; Ghasemi Y
    Mol Cell Probes; 2019 Dec; 48():101446. PubMed ID: 31520715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection.
    Chen A; Mann B; Gao G; Heath R; King J; Maissoneuve J; Alderson M; Tate A; Hollingshead SK; Tweten RK; Briles DE; Tuomanen EI; Paton JC
    Clin Vaccine Immunol; 2015 Oct; 22(10):1079-89. PubMed ID: 26245351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine.
    Dorosti H; Eslami M; Negahdaripour M; Ghoshoon MB; Gholami A; Heidari R; Dehshahri A; Erfani N; Nezafat N; Ghasemi Y
    J Biomol Struct Dyn; 2019 Aug; 37(13):3524-3535. PubMed ID: 30634893
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage.
    Palaniappan R; Singh S; Singh UP; Sakthivel SK; Ades EW; Briles DE; Hollingshead SK; Paton JC; Sampson JS; Lillard JW
    Infect Immun; 2005 Feb; 73(2):1006-13. PubMed ID: 15664944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcutaneous immunization with pneumococcal surface protein A in mice.
    Nagano H; Kawabata M; Sugita G; Tsuruhara A; Ohori J; Jimura T; Miyashita K; Kurono Y; Tomonaga K; Briles DE; Fujihashi K
    Laryngoscope; 2018 Mar; 128(3):E91-E96. PubMed ID: 29226330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults.
    Baril L; Dietemann J; Essevaz-Roulet M; Béniguel L; Coan P; Briles DE; Guy B; Cozon G
    Clin Exp Immunol; 2006 Aug; 145(2):277-86. PubMed ID: 16879247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.